α硫辛酸联合莫沙必利治疗糖尿病胃轻瘫的效果观察  

Effects of α-lipoic acid combined with mosapride in the treatment of diabetic gastroparesis

作　　者：寇小兵 KOU Xiao-bing(Department of Endocrinology,Xuchang Central Hospital,Xuchang 461000,Henan,China)

机构地区：[1]许昌市中心医院内分泌科,河南许昌461000

出　　处：《中国校医》2022年第2期146-148,共3页Chinese Journal of School Doctor

摘　　要：目的探讨α硫辛酸联合莫沙必利对糖尿病性胃轻瘫(DGP)患者氧化应激及肠道菌群的影响。方法选择2019年1月—2020年2月本院收治的84例DGP患者,采用随机双盲法分为2组,各42例。在控制饮食及血糖基础上,观察组采用α硫辛酸+莫沙必利治疗,对照组单用莫沙必利治疗,均持续治疗3周。比较两组血清中氧化应激指标[谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、活性氧(ROS)]和粪便中肠道菌群(乳酸杆菌、双歧杆菌、肠球菌、肠杆菌)菌落形成单位对数值(lgCFU/g)。结果治疗3周后,观察组GSH-Px、SOD水平为:(28.24±2.83)umoL/L、(275.38±27.54)IU/m,均高于治疗前的(23.37±2.34)umoL/L、(219.57±19.88)IU/m(t=8.612、10.648,P值均<0.05),ROS为(587.41±60.11)IU/m低于治疗前的(660.15±68.02)IU/m,对照组治疗3周后GSHPx、SOD水平为:(25.49±2.66)umoL/L、(248.91±25.97)IU/m,均低于观察组(t=4.589、4.532,P值均<0.05),ROS为(623.24±65.38)IU/m,高于观察组(t=2.615,P<0.05);治疗3周后,观察组乳酸杆菌、双歧杆菌为(8.36±0.45)、(8.98±0.42)lgCFU/g,均高于治疗前的(7.04±0.23)、(8.35±0.31)lgCFU/g,(t=16.927、7.821,P值均<0.05),肠球菌、肠杆菌为(7.65±0.12)、(6.32±0.10)lgCFU/g,低于治疗前的(8.24±0.27)、(6.83±0.26),(t=12.941、11.865,P值均<0.05),对照组治疗后乳酸杆菌、双歧杆菌为(8.11±0.34)、(8.79±0.38)lgCFU/g,均低于观察组(t=2.873、2.174,P值均<0.05),肠球菌、肠杆菌为(7.99±0.18)、(6.61±0.17)lgCFU/g,均高于观察组(t=10.186、9.529,P值均<0.05)。结论采用α硫辛酸联合莫沙必利治疗DGP患者,可有效降低氧化应激反应,调节肠道菌群紊乱,值得推广。Objective To investigate the effect of α-lipoic acid combined with mosapride on oxidative stress and intestinal flora in patients with diabetic gastroparesis(DGP).Methods A total of 84 DGP patients admitted to our hospital from January 2019 to February 2020 were selected and divided into an observation group and a control group by the random double-blind method,with 42 cases in each group.On the basis of diet and blood sugar control,the observation group was treated with α-lipoic acid combined with mosapride,and the control group was treated with mosapride alone,and the treatment lasted for 3 weeks.The oxidative stress indicators [glutathione peroxidase(GSH-Px),superoxide dismutase(SOD),and reactive oxygen species(ROS)] in serum and the colony forming unit logarithm(lgCFU/g) of intestinal flora(Lactobacillus,Bifidobacterium,Enterococcus and Enterobacter) in feces were compared between the two groups.Results After 3 weeks of the treatment,the levels of GSH PX and SOD in the observation group were:(28.24 ± 2.83) umol/L and(275.38 ± 27.54) IU/m,which were higher than those before the treatment:(23.37 ± 2.34) umol/L and(219.57 ± 19.88) IU/M respectively(t = 8.612,10.648,both P < 0.05),ROS was(587.41 ± 60.11) IU/m,which was lower than that before the treatment:(660.15 ± 68.02) IU/m,and the levels of GSH PX and SOD in the control group were(25.49 ± 2.66) umol/L and(248.91 ± 25.97) IU/m,lower than those in the observation group(t = 4.589,4.532,both P < 0.05),ROS was(623.24 ± 65.38) IU/m,higher than that in the observation group(t = 2.615,P < 0.05).After 3 weeks of the treatment,Lactobacillus and Bifidobacterium in the observation group were(8.36 ± 0.45) lgCFU/g and(8.98 ± 0.42) lgCFU/g,higher than those before the treatment:(7.04 ± 0.23) lgCFU/g and(8.35 ± 0.31) lgCFU/g,(t = 16.927,7.821,both P < 0.05),Enterococcus and Enterobacter were(7.65 ± 0.12) lgCFU/g and(6.32 ± 0.10) lgCFU/g,which were lower than those before the treatment:(8.24 ± 0.27) lgCFU/g and(6.83 ± 0.26) lgCFU/g respectively(t = 12.941,1

关 键 词：糖尿病性胃轻瘫 Α硫辛酸 莫沙必利 氧化应激 肠道菌群 

分 类 号：R587.1[医药卫生—内分泌] R453[医药卫生—内科学]